Research programme: antibody therapeutics - Argenx
Latest Information Update: 22 Apr 2021
At a glance
- Originator argenx
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 22 Apr 2021 Research programme: antibody therapeutics - Argenx is available for licensing as of 22 Apr 2021. https://www.argenx.com/innovation#partnering-opportunities
- 12 Apr 2021 FairJourney Biologics enters into a collaboration with argenx to leverage IONTAS’ mammalian display technology to develop antibody therapeutics for Immunological disorders
- 12 Apr 2021 Early research in Immunological disorders in Netherlands (Parenteral)